NASDAQ:FTXH First Trust Nasdaq Pharmaceuticals ETF (FTXH) Price, Holdings, & News $27.99 +0.12 (+0.42%) As of 02/21/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrends About First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FTXH alerts:Sign Up Key Stats Today's Range$27.99▼$28.0050-Day Range$26.74▼$28.0052-Week Range$25.73▼$29.72Volume475 shsAverage Volume3,349 shsMarket Capitalization$13.99 millionAssets Under Management$15.33 millionDividend Yield1.57%Net Expense Ratio0.60%Aggregate RatingModerate Buy ETF OverviewThe First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.Read More… First Trust Nasdaq Pharmaceuticals ETF ExpensesTypeFTXHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.60%0.57%0.56%0.51%0.53%Other Expenses0.00%0.30%0.50%0.47%0.53%Total Expense0.60%0.70%0.72%0.67%0.71%Fee Waiver0.00%-0.45%-0.50%-0.32%-0.56%Net Expense0.60%0.61%0.62%0.60%0.60% Receive FTXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Trust Nasdaq Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address FTXH ETF News HeadlinesFirst Trust Nasdaq BuyWrite Income ETF declares $0.207 dividendJanuary 22, 2025 | msn.com3 Health Care ETFs You'll Want to Own When the Market RecoversAugust 3, 2022 | stocknews.comCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?February 22, 2025 | Investors Alley (Ad)Surprising Analyst 12-Month Target For FTXHMay 25, 2022 | nasdaq.comFirst Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.0488March 25, 2022 | seekingalpha.comSolid Q4 Earnings Fail to Impress Pharma ETFsFebruary 22, 2022 | nasdaq.comSee More Headlines FTXH ETF - Frequently Asked Questions How have FTXH shares performed this year? First Trust Nasdaq Pharmaceuticals ETF's stock was trading at $26.97 at the beginning of 2025. Since then, FTXH shares have increased by 3.8% and is now trading at $27.9860. View the best growth stocks for 2025 here. Who are First Trust Nasdaq Pharmaceuticals ETF's major shareholders? First Trust Nasdaq Pharmaceuticals ETF's top institutional shareholders include LPL Financial LLC (11.18%), Envestnet Asset Management Inc. (3.28%), Summit Investment Advisors Inc. (2.83%) and Vivaldi Capital Management LP (1.74%). How do I buy shares of First Trust Nasdaq Pharmaceuticals ETF? Shares of FTXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of First Trust Nasdaq Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that First Trust Nasdaq Pharmaceuticals ETF investors own include Digirad (DRAD), RAIT Financial Trust (RAS), Cummins (CMI), Auxly Cannabis Group (CBWTF), Blueknight Energy Partners (BKEP), Biocept (BIOC) and BioCorRx (BICX). Fund Details IssuerFirst Trust Fund NameFirst Trust Nasdaq Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:FTXH Inception Date9/20/2016 Fund ManagerDaniel Lindquist, Jon Erickson, David McGarel, Roger Testin, Stan Ueland, Chris Peterson, Erik Russo WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkNasdaq US Smart Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings51 Fund Statistics Assets Under Management$15.33 million Average Daily Volume$4,352.60 Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorFirst Trust Advisors L.P. CustodianThe Bank of New York Mellon Corporation DistributorFirst Trust Portfolios L.P. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerOld Mission Options OptionableN/A Short Interest1,200 shs Miscellaneous Outstanding Shares500,000Beta0.70 Creation Unit50,000 Creation Fee$500.00 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Top 10 FTXH HoldingsBristol-Myers Squibb (NYSE:BMY)Holding Weight: 8.75%AbbVie (NYSE:ABBV)Holding Weight: 7.64%Johnson & Johnson (NYSE:JNJ)Holding Weight: 7.36%Pfizer (NYSE:PFE)Holding Weight: 6.88%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 5.71%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.76%Cardinal Health (NYSE:CAH)Holding Weight: 4.45%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.72%Zoetis (NYSE:ZTS)Holding Weight: 3.71%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.67%Full Holdings DetailsFTXH Sector ExposureFTXH Industry Exposure This page (NASDAQ:FTXH) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.